Home / Transcripts / Definium Therapeutics, Inc. (DFTX) · August 6, 2026

Definium Therapeutics, Inc. (DFTX) Earnings Call Transcript

August 6, 2026

NASDAQ US Health Care Pharmaceuticals earnings 18 min

Earnings Call Speaker Segments

Gitanjali Jain executive
#1

Hello, everyone, and welcome. I'm Gita Jain, Head of Investor Relations. We appreciate your joining us for this Definium Therapeutics call about our Q2 2026 financial results and latest developments. Those on the line are in listen-only mode. A live webcast is accessible through the investor section of Definium's site at definiumtx.com, and once it concludes, a replay will be posted. Today's discussion will be led by Rob Barrow, our Chief Executive Officer, and with him are Dr. Dan Karlin, our Chief Medical Officer, and Brandi Roberts, our Chief Commercial Officer. During this call, we'll share some forward-looking statements. These cover things like how safe and effective our product candidates might be, how they might progress through regulatory and clinical stages, how long our cash will last, and what we expect, plan, and hope for regarding partnerships and future prospects. Various risks could impact what we say, including changes in market conditions and difficulties related to research, development, and getting regulatory approval. You can find these and other risk factors described in the documents we've filed with the SEC and the relevant Canadian securities regulators, which include our annual report on Form 10-K and the Form 10-Q we filed today. Statements about the future depend on what management assumes, believes, and estimates on the day those statements get made — among those assumptions being that the dangers and unknowns laid out in documents filed with the SEC and the relevant Canadian securities regulators won't materialize, and that nothing else of significance will happen beyond Definium's ordinary business activities. Don't put excessive weight on these forward-looking statements, which are being given as of today, August 6th, 2026. Definium takes on no duty to revise such statements, including in situations where management's thinking shifts, unless the law demands it. We said in the earnings release that we expect to share topline data from VOYAGE — the initial phase III trial of DT120 ODT in generalized anxiety disorder, or GAD — sometime during the week of August 10th, 2026. Given that timing, there won't be a Q&A portion once today's prepared remarks wrap up. I'll now hand things over to Rob.

Rob Barrow executive
#2

Thank you, Gita, and thanks to all of you for being here today. For many years, the field of psychiatry has been waiting for treatments that could truly alter what happens for patients. Our view is that this future is starting to become visible. The level of unmet need has never been higher, and more and more people recognize that patients are entitled to therapies that can produce transformational results; we take pride in Definium's role at the forefront of shaping this new era, generating pivotal evidence for DT120 ODT as we pursue a best-in-class profile and aim at some of the biggest and least served indications in psychiatry. For our company, the opening six months of this year represented a crucial stretch of inflection and growth. During June, we announced positive top-line findings from EMERGE, the initial phase III trial of DT120 ODT in major depressive disorder, or MDD. Those findings set a fresh standard for the field, since they showed what we consider the biggest treatment effect ever seen in a phase III MDD study. When considered as a whole, the swift and lasting efficacy along with the favorable tolerability we have seen consistently across the DT120 development program bolsters our conviction that DT120 could substantially reshape the treatment paradigm for patients suffering from anxiety, depression, and PTSD. We have kept making substantial strides throughout our pipeline, having finished enrollment in VOYAGE and PANORAMA, our pair of phase III trials in GAD, opened enrollment in ASCEND, our second phase III study in MDD, from which we anticipate top-line data during 2027, and moved ahead with preparations for HAVEN, our planned phase III trial in PTSD, which we expect to begin in 2027. As we look forward, we find ourselves in what we consider one of the most consequential stretches in our company's history. In the coming week, we intend to report top-line results from VOYAGE, and we anticipate reporting top-line results from PANORAMA during September. Since no new drug has won approval for this highly prevalent and burdensome disorder in nearly 20 years, we see an exceptional chance to provide a first and best-in-class treatment for GAD. Alongside our clinical momentum, we keep efficiently moving toward a possible NDA submission for DT120 ODT. Across the development program, we have collaborated closely with FDA, sustaining a constructive dialogue that has informed our program and matched expectations for the field; we believe the agency's recently finalized guidance closely mirrors this alignment and the principles that have steered our regulatory strategy since the beginning. We have also kept growing and reinforcing our organization so we can deliver on the clinical, regulatory, and commercial milestones that lie ahead. During this year, we have considerably broadened our commercial capabilities to prepare for the possible launch of DT120 ODT if approved, and we have bolstered our balance sheet through an upsized public offering that brought in roughly $805 million in gross proceeds. Given the strength of our finances and the momentum we have in operations, we're in a good position to keep moving our R&D programs forward and get ready to launch DT120 ODT in a way that matches the size of the commercial opportunity and, even more crucially, how great the patient need is. What we've achieved comes from our team executing with discipline and from our dedication to bringing real value to patients and shareholders. So with that, I'll hand things over to Dan, who will walk through our clinical programs in greater detail.

Dan Karlin executive
#3

As Rob mentioned, the encouraging results from the phase III EMERGE trial represent a significant leap — not just for the DT120 program, but for the entire field of psychiatry. Speaking as a psychiatrist, what excites me most is how steady DT120 ODT's profile has remained across the whole development effort: rapid onset of action, enduring clinical improvement, and good tolerability. We believe that combination has the potential to transform treatment approaches for anxiety, depression, and PTSD. A total of 149 individuals suffering from moderate to severe MDD were enrolled in EMERGE. In this group of study participants, the average MADRS — that's the Montgomery-Åsberg Depression Rating Scale — score at baseline was 34.5, and about 50% of them had previously not responded to at least two antidepressant treatments. Prior to randomization, any antidepressant and anxiolytic medications they had been taking in the background were stopped, and psychotherapy was not included as part of the study, which allowed us to evaluate DT120 as a genuine monotherapy. All primary and key secondary endpoints were achieved, with results that were highly statistically significant across several clinically meaningful measures. For the MADRS at week six, DT120 demonstrated an 8.1 point improvement versus placebo, with a P value below 0.0001, equivalent to an effect size of roughly 0.83 on the primary endpoint. From what we understand, no phase III study in MDD has ever shown a treatment effect of this size. What's more, the drug's benefit showed up by week one following just one dose of DT120 ODT, remained statistically significant at each later check, and was still present at week 12. Alongside the primary endpoint, every important secondary measure improved to a statistically significant degree, and tolerability looked favorable. These EMERGE findings give us tremendous encouragement, and we're eager to bring forward pivotal results in GAD. Millions of people around the globe live with GAD, and yet the available treatments haven't shifted in twenty years. Even with the drugs that have been approved and are available, a lot of patients still don't get their symptoms under control well enough, they wait too long before feeling any benefit, they deal with side effects that are hard to tolerate, and they carry the daily burden of long-term medication. DT120 takes a completely different approach. The goal is fast, lasting clinical improvement from just one treatment session, which can then be boosted through occasional retreatment when a patient's situation calls for it. What gives us confidence in the DT120 program is how consistent the data have been so far. In our phase II GAD trial, DT120 produced quick, clinically meaningful gains that held up for 12 weeks after patients were treated. With VOYAGE and PANORAMA, the aim is to confirm those results rigorously across two separate, well-controlled pivotal trials. When we first put together VOYAGE and PANORAMA, the power they were built to have was roughly 90% for picking up a five-point treatment effect after adjusting for placebo. Then came the protocol-specified blinded sample size re-estimation, which looked at different versions of the primary outcome measure along with dropout rates. According to that analysis, you'd now expect both studies to exceed 99% power for detecting a five-point placebo-adjusted treatment effect. The notable piece here is this: even though these trials were statistically equipped to catch a 5-point difference, we believe that a 4-point-or-better improvement relative to placebo at 12 weeks would compare favorably with what's currently on the market as well as with other investigational candidates in development. In addition to DT120, we keep moving DT402 forward in autism spectrum disorder, or ASD; in our view, this program is a meaningful long-term opportunity because of the substantial unmet need and the fact that no FDA-approved therapies exist that tackle head-on the core social communication difficulties tied to ASD. Throughout these development programs, we are tremendously enthusiastic about the data we have generated so far and the data we anticipate reporting in the near future. I'll now hand the call to Matt so he can discuss our commercial preparations underway as we work to turn clinical excellence into commercial success.

Matt Wiley executive
#4

Thanks, Dan. It's great to take a few minutes to talk about how our commercial momentum for DT120 keeps building, and the positive phase III EMERGE results have made that even stronger; those findings leave us more confident that DT120 can provide meaningful, rapid, and durable benefit to patients living with MDD and GAD. During our market research, patients in both groups made clear they are unhappy with the treatments available today and reacted favorably to the DT120 product profile. Right after EMERGE, we are acting quickly to keep constructing a completely integrated commercial organization meant to capture the full adoption potential of DT120 should it be approved. One strong recent illustration of that execution is the Wired for Worry campaign we started in July; it aims to increase awareness of the ongoing burden and underlying neurobiology of GAD, bring key unmet needs into focus, and help clinicians better spot patients who might benefit from new treatment choices. The initial response has been very favorable, and the campaign is already generating substantial engagement as we approach the coming GAD data readouts. Meanwhile, we are growing our commercial group at a fast pace and establishing the operational capabilities that matter most; we are bringing in and onboarding essential talent in marketing, market access, sales, and commercial operations while carrying out key launch work, such as promotional message development, payer value narratives and engagement, distribution model design, and detailed deployment planning; these activities are moving forward alongside the creation of our centralized patient support services, reimbursement pathways, and field operational readiness, and our HCP engagement initiatives all come together to support a strong, seamless launch. As we do all this, our attention stays on giving patients and providers an outstanding experience, drawing on the same distinctive insights and disciplined execution that shape our R&D approach. We have great confidence in DT120's clinical profile, our go-to-market strategy, and how ready we are commercially. We think our recent MDD data and the upcoming GAD pivotal data, together with momentum from market conditioning efforts and our faster infrastructure build, put Definium in an excellent position for a successful launch and to set the standard for this new and exciting treatment modality. With that, I'll hand things over to Brandi for our financial results.

Brandi Roberts executive
#5

Thanks, Matt. Prior to walking through the numbers, I want to take a moment to talk about the financing we closed in the quarter and what it means for where Definium is headed in the coming years. During June, we wrapped up an underwritten public offering that was upsized and brought in roughly $758 million of net proceeds. The strong turnout from investors already on our register as well as new ones was gratifying, and in our view this successful raise speaks to rising confidence in DT120, the wider pipeline we're building, and the long-term vision we hold for the company. A key point is that this transaction materially bolstered our balance sheet, and we closed the quarter with about $1.1 billion across cash equivalents and investments. Given the operating plans we have today, we expect that capital to be enough to fund planned operations all the way into 2030. With this strong financial footing, we have the resources to carry out our strategy and preserve financial flexibility at the same time. Should DT120 win approval, we aim to make sure it gets to the patients who need it and the providers who for a long time have wanted better treatment choices. We're continuing to invest heavily in market access, medical affairs, provider education, patient support programs, and other key launch activities, while at the same time moving forward our pivotal DT120 programs, the DT402 program, and the rest of our R&D pipeline. In our view, that puts us in position to capture the fullest opportunity for DT120 and to keep creating long-term value throughout the organization. Let me now move to the financial results for the second quarter of 2026, which you can find laid out in the earnings press release that went out this afternoon. R&D expenses came to $48.7 million in the second quarter of 2026, versus $29.8 million during the same period a year earlier. That step-up was mainly the result of greater DT120 program spend and added personnel costs tied to our expansion of R&D capabilities. G&A expenses totaled $26.4 million, versus $11.1 million in the second quarter of 2025. That rise largely came from higher stock-based compensation, corporate and government affairs work, personnel-related costs, and investments in commercial readiness. The year-over-year growth in both R&D and G&A reflects our ongoing investment in the clinical development programs, commercial readiness work, and wider organizational capabilities as we get ready for possible commercialization. On the whole, operating expenses for the quarter came in as we had expected internally. Net loss for the second quarter of 2026 reached $159 million, versus $42.7 million in the second quarter of 2025. Keep in mind that net loss can swing considerably because of changes in the fair value of our 2022 USD financing warrants, which get marked to market every quarter. In the second quarter, the change in fair value of those warrants produced an $86.2 million non-cash expense, mostly reflecting our share price climbing from $18.90 on March 31st, 2026, to $47.04 on June 30th, 2026. Looking forward, we'll keep concentrating on executing with discipline and allocating capital thoughtfully. A significant stretch lies before us, and in our view, the strength of our financial position provides the room to put money into what matters most, all while generating lasting worth for patients as well as shareholders. So with that, I'll hand things back over to Rob.

Rob Barrow executive
#6

Thank you, Brandi. My heartfelt appreciation goes out to everyone at Definium for the relentless effort that has made our achievements possible. What we have accomplished so far is the product of many years of scientific discipline, consistent execution, and a steadfast dedication to creating treatments capable of genuinely enhancing the lives of people who suffer from anxiety, depression, PTSD, and other severe psychiatric conditions. During my opening remarks on this call, I noted that a new era for psychiatric treatment is approaching, and our enthusiasm and excitement about helping lead the effort to turn that possibility into reality could not be greater. To advance that goal, our attention stays firmly fixed on delivering the clinical, regulatory, and commercial milestones that lie before us. Since top-line data from Voyage are expected to be announced next week, no question and answer portion will take place after today's call. Once those results are available, we look forward to a more detailed discussion of them, and we appreciate your ongoing backing of Definium.

Gitanjali Jain executive
#7

That concludes today's session. You may now disconnect.

For developers and AI pipelines

Programmatic access to Definium Therapeutics, Inc. earnings transcripts and 132,000+ others is available through the EarningsAPI REST API and the hosted MCP server. Quarterly plans from $162 - full transcripts, speaker segments, full-text search, and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.